2025
Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease
Qiu Y, Jacobs D, Messer K, Salmon D, Wellington C, Stukas S, Revta C, Brewer J, Léger G, Askew B, Donahue L, Kaplita S, Coric V, Qureshi I, Feldman H. Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease. Alzheimer's Research & Therapy 2025, 17: 97. PMID: 40317057, PMCID: PMC12046789, DOI: 10.1186/s13195-025-01745-3.Peer-Reviewed Original ResearchConceptsMild to moderate ADADAS-cog11CDR-SBBaseline plasma NfLAlzheimer's diseasePlasma biomarkersMild-to-moderate Alzheimer's diseasePrognostic valueClinical trialsBaseline NfLPlasma NfLPlacebo-controlled trialCortical volumeConcentrations of plasma biomarkersMethodsPost hoc analysisDesign of clinical trialsClinical outcome dataIncreased ventricular volumeTrial participantsVolumetric MRIBaseline concentrationsEarly disease stagesClinical trial designTrial entry criteriaAD trials
2024
The early-onset Alzheimer’s disease MRI signature: a replication and extension analysis in early-stage AD
Mehta R, Keith C, Teixeira C, Worhunsky P, Phelps H, Ward M, Miller M, Navia R, Pockl S, Rajabalee N, Coleman M, D’Haese P, Rezai A, Wilhelmsen K, Haut M. The early-onset Alzheimer’s disease MRI signature: a replication and extension analysis in early-stage AD. Cerebral Cortex 2024, 34: bhae475. PMID: 39714256, PMCID: PMC11664631, DOI: 10.1093/cercor/bhae475.Peer-Reviewed Original ResearchConceptsEarly-onset Alzheimer's diseaseLate-onset Alzheimer's diseaseNon-AD pathologyCognitively normal individualsManagement of personsCortical atrophyFunctional statusEarly-stage ADRural populationAlzheimer's diseaseDisease stageLongitudinal studyCortical signatureWhole-brainCortical thinningCortical analysisClinical cohortNormal individualsClinical effectsSignature regionsIndividualsPersonsEarly disease stagesMRI signatures
2023
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)
Tentori C, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Berrocal J, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao L, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, Chiusolo P, Giaccone L, Voso M, Bewersdorf J, Nibourel O, Díaz-Beyá M, Jerez A, Hernandez F, Kennedy K, Xicoy B, Ubezio M, Campagna A, Russo A, Todisco G, Mannina D, Bramanti S, Zampini M, Riva E, Bicchieri M, Asti G, Viviani F, Buizza A, Tinterri B, Bacigalupo A, Rambaldi A, Passamonti F, Ciceri F, Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kordasti S, Santini V, Sanz G, Kern W, Kubasch A, Platzbecker U, Diez-Campelo M, Maciejewski J, Ades L, Fenaux P, Haferlach T, Zeidan A, Castellani G, Komrokji R, Ieva F, Della Porta M. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS). Blood 2023, 142: 197. DOI: 10.1182/blood-2023-182194.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationStem cell transplantationMyelodysplastic syndromeProlonged life expectancyClinical outcomesOptimal timingCell transplantationLife expectancyValidation cohortImmediate transplantationTransplantation policyRisks of HSCTImmediate hematopoietic stem cell transplantationAllogeneic hematopoietic stem cell transplantationAge groupsDiagnosis of MDSConventional prognostic scoresPost-HSCT outcomesLow-risk diseaseTiming of transplantationDisease-modifying therapiesEarly disease stagesPatient's life expectancyAverage survival timeDifferent time points
2021
Predictive value of NT-proBNP in non-obstructive hypertrophic cardiomyopathy
Hutt E, Mentias A, Alashi A, Fava A, Popovic Z, Thamilarasan M, Lever H, Desai M. Predictive value of NT-proBNP in non-obstructive hypertrophic cardiomyopathy. European Heart Journal 2021, 42: ehab724.0765. DOI: 10.1093/eurheartj/ehab724.0765.Peer-Reviewed Original ResearchNT-proBNP ratioLV ejection fractionSerum NT-proBNPNT-proBNPAsymptomatic patientsPrimary endpointSeptal myectomySudden cardiac death risk factorsNon-obstructive hypertrophic cardiomyopathyKaplan-Meier survival analysisDeath risk factorsEarly disease stagesHypertrophic cardiomyopathy patientsImplantable defibrillator dischargesEjection fractionHeart transplantPrimary outcomeRisk stratificationPrognostic valueAdverse outcomesDisease stageCardiomyopathy patientsRisk factorsEcho variablesHypertrophic cardiomyopathy
2020
Amelanotic melanoma of the head and neck: analysis of tumor characteristics from the National Cancer Database
Huayllani MT, Boczar D, Saleem HY, Spaulding AC, Bagaria SP, Lu X, Kassis S, Perdikis G, Forte AJ. Amelanotic melanoma of the head and neck: analysis of tumor characteristics from the National Cancer Database. International Journal Of Dermatology 2020, 60: 347-351. PMID: 33040374, DOI: 10.1111/ijd.15243.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseTumor characteristicsAmelanotic melanomaBreslow depthCancer DatabaseMitotic countCommon malignant melanomaPresence of ulcerationEarly disease stagesYears of ageRare subtypeDisease stageCutaneous melanomaMalignant melanomaMelanomaOlder ageAMHNPatientsNeckStatistical differenceUlcerationAgeHeadCountLymph
2019
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal Of Autoimmunity 2019, 105: 102328. PMID: 31548157, DOI: 10.1016/j.jaut.2019.102328.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisAnti-mitochondrial autoantibodiesBiochemical cholestasisBiliary cholangitisBiliary epitheliumUrsodeoxycholic acidPBC-specific anti-nuclear antibodiesBile acidsToxic hydrophobic bile acidsAutoimmune liver diseaseSecond-line treatmentFirst-line treatmentAnti-nuclear antibodiesReliable disease markersEarly disease stagesCholestatic biochemical profileNew therapeutic approachesHydrophobic bile acidsAutoimmune originSeronegative casesLiver histologyAutoimmune attackFemale preponderanceHistologic confirmationImmunologic pathways
2018
Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions
Kaunzner UW, Kang Y, Zhang S, Morris E, Yao Y, Pandya S, Rua S, Park C, Gillen KM, Nguyen TD, Wang Y, Pitt D, Gauthier SA. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain 2018, 142: 133-145. PMID: 30561514, PMCID: PMC6308309, DOI: 10.1093/brain/awy296.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticBrainCarbon RadioisotopesChronic DiseaseCross-Sectional StudiesFemaleHumansInflammationIronIsoquinolinesMacrophagesMagnetic Resonance ImagingMaleMicrogliaMiddle AgedMultiple SclerosisPositron-Emission TomographyRetrospective StudiesYoung AdultConceptsChronic active lesionsMultiple sclerosisChronic lesionsActive lesionsMultiple sclerosis lesionsHyperintense rimQuantitative susceptibility mappingChronic active multiple sclerosis lesionsSclerosis lesionsChronic multiple sclerosis lesionsActive multiple sclerosis lesionsPersistent inflammatory activityProgressive multiple sclerosisMicroglia/macrophagesInnate immune activationEarly disease stagesTranslocator proteinGreater tissue damagePost-mortem studiesProgressive patientsActivated microgliaInflammatory activityPersistent inflammationImmune activationDisease stage
2016
Changes in functional organization and white matter integrity in the connectome in Parkinson's disease
Tinaz S, Lauro PM, Ghosh P, Lungu C, Horovitz SG. Changes in functional organization and white matter integrity in the connectome in Parkinson's disease. NeuroImage Clinical 2016, 13: 395-404. PMID: 28116232, PMCID: PMC5226806, DOI: 10.1016/j.nicl.2016.12.019.Peer-Reviewed Original ResearchConceptsParkinson's diseaseWhite matter integrityPD patientsPD groupWhite matter connectivity changesResting-state functional MRINon-demented PD patientsEarly disease stagesCortico-striatal circuitsWhite matter connectivityDopaminergic medicationDorsal attention networkDisease stageFunctional organizationSensorimotor networkWhole-brain connectomeFunctional modular organizationWhite matterFunctional MRIConnectivity changesDiseasePatientsDiffusion tensorDefault modeBrain connectome
1995
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H, Giai M, Diamandis E, Katsaros D, Sutherland D, Levesque M, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Research 1995, 55: 2104-10. PMID: 7538047.Peer-Reviewed Original ResearchConceptsProstate-specific antigenIR-PSABreast cancerCox proportional hazards regression modelEstrogen receptor-negative patientsEstrogen receptor-positive tumorsProportional hazards regression modelsIndependent favorable prognostic markerReceptor-negative patientsNode-positive patientsFavorable prognostic indicatorSurvival of patientsReceptor-positive tumorsRelapse-free survivalBreast cancer patientsFemale breast cancerHazards regression modelsEarly disease stagesFavorable prognostic markerProstatic epithelial cellsPSA statusBetter prognosisPositive tumorsPrognostic valueDisease stage
1994
Detection of prostate-specific antigen immunoreactivity in breast tumors
Diamandis E, Yu H, Sutherland D. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Research And Treatment 1994, 32: 301-310. PMID: 7532468, DOI: 10.1007/bf00666007.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPSA immunoreactivityProgesterone receptorP53 tumor suppressor gene productBreast tumorsProstate-specific antigen immunoreactivitySeminal prostate-specific antigenProgesterone receptor-positive tumorsSensitive immunofluorometric procedureReceptor-positive tumorsEarly disease stagesTumor suppressor gene productBreast tumor extractsSuppressor gene productWestern blot analysisDisease stageProstate carcinomaAntigen immunoreactivityTumor extractsTumor specimensClinical practiceImmunoreactivityTumorsYoung womenImmunofluorometric procedure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply